OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

American Society of Anesthesiologists and attorney Scott Lassman say in comments submitted to docket for meeting of FDA’s Nonprescription Drug and Anesthetic and Analgesic Drug Products they disagree with agency’s suggestion studies showing all naloxone products in all delivery formats can be used safely OTC point to all the products moving to nonprescription.

• Source: Shutterstock

Making all naloxone products available OTC in the US could limit, not expand access to the opioid overdose treatment, according to comments submitted before a panel of Food and Drug Administration advisors discusses the first naloxone switch proposal, for a nasal spray.

The American Society of Anestiologists and attorney Scott Lassman both made clear in comments, submitted to the docket for a...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health